Eveline Van Keymeulen

Eveline Van Keymeulen

Partner, Latham & Watkins LLP
[email protected]

Eveline Van Keymeulen is a partner in Latham & Watkins’ Brussels and Paris offices and is a member of the firm’s healthcare and life sciences practice.

Ms Van Keymeulen advises multinational companies and start-ups in the pharmaceutical, biotech, medical devices, cosmetics and food and beverage sectors on a broad variety of complex European, domestic and cross-border regulatory matters, including clinical trials, product approvals, regulatory incentives, market access, promotion and advertising, post-market obligations and general compliance matters.

In addition, Ms Van Keymeulen has extensive experience advising on medical cannabis and hemp-based product regulations. She successfully challenged the legality of French hemp regulations in the first case related to cannabidiol (CBD) products before the Court of Justice of the European Union (Case C-663/18, Kanavape). This landmark judgment had a major impact on the development of the European CBD industry.

Ms Van Keymeulen is ranked in Chambers for life sciences: regulatory (since 2020) and recognised as a ‘Rising Star’ and ‘Next Generation Lawyer’ in healthcare and life sciences by The Legal 500 (since 2018). She is considered a ‘National Leader’ and a ‘Global Leader’ by Who’s Who Legal: Life Sciences (since 2016) and is further recognised as one of the leading life sciences practitioners in France by Legal Media Group 2021, Best Lawyers in France 2021 and Euromoney’s Women in Business Law Expert Guide 2021. Ms Van Keymeulen was also recognised as ‘European Advisory Lawyer of the Year’ (2021) by, and won ‘Impact Deal of the Year’ at, the prestigious Europe LMG Life Sciences Awards (2021–2022). Clients particularly value her ‘high level of energy’, and appreciate her for ‘being extremely flexible and genuinely engaged’ as well as having a ‘can do attitude’ while some have even called her a ‘rock star’.

Ms Van Keymeulen has authored numerous articles and has been a featured speaker on EU regulatory matters at prominent conferences such as the Pharmaceutical Law Academy in Cambridge. She also serves on the editorial board of the European Pharmaceutical Law Review. In addition, she has been quoted in ‘BBC Business Daily’, Bloomberg, The Times, Les Echos and other leading international business journals on life sciences regulatory and policy matters.

Content from this author

Unlock unlimited access to all Global Competition Review content